Study in Uganda Shows COVID-19 Promotes Harmful Gut Bacteria Growth

Medical News: A new study conducted in Uganda has revealed how COVID-19 may lead to severe illness by promoting the overgrowth of harmful bacteria in the gut, specifically Enterococcus species. The research highlights the significant role the gut microbiome plays in how COVID-19 progresses, suggesting that this bacterial overgrowth could be linked to the worsening of symptoms in infected individuals.


COVID-19 Promotes Harmful Gut Bacteria Growth

Investigating the Gut Microbiome
Researchers from several institutions, including the University of California, Berkeley, and Makerere University in Uganda, teamed up to examine the gut microbiomes of individuals with COVID-19. This Medical News report provides an overview of their findings. The team studied stool samples from 114 symptomatic COVID-19 patients and compared them to samples from 76 asymptomatic household members. Their aim was to explore whether changes in gut bacteria might influence the severity of COVID-19 symptoms.
 
Gut bacteria play a crucial role in maintaining a healthy immune system. The microbiome, which is the community of microorganisms living in our intestines, can help protect against harmful pathogens. However, during illnesses like COVID-19, this balance is often disrupted. Researchers believe that this imbalance, called dysbiosis, may be connected to the severity of the disease.
 
Key Findings: Enterococcus Blooms and COVID-19
The study revealed a significant reduction in gut bacterial diversity among COVID-19 patients. This loss of diversity was accompanied by an overgrowth, or "bloom," of harmful bacteria like Enterococcus and Eggerthella species. These bacterial blooms were absent in the asymptomatic household members, suggesting that this overgrowth could be tied to the disease itself.
 
The researchers found that Enterococcus was present in 56.6% of COVID-19 patients, while it was completely absent in asymptomatic controls. In some COVID-19 patients, Enterococcus levels made up as much as 85% of their total gut bacteria. Similarly, Eggerthella species, found in only 2% of the control group, were detected in 43.4% of COVID-19 cases.
 
The overgrowth of Enterococcus is particularly concerning because this bacterium is associated with hospital-acquired infections, including bloodstream infections and urinary tract infections. Its presence in such large numbers in COVID-19 patients may be a marker of disease severity or a potential cause of worsened outcomes.
 
How COVID-19 and the Gut Are Linked
The connection between COVID-19 and gut bacteria like Enterococcus is complex. The disease primarily affects the lungs, but it has also been known to cause gastrointestinal symptoms such as diarrhea, nausea, and vomiting. This indicates that the virus can infect the gut as well as the respiratory tract. The researchers suspect that this gut infection may disrupt the immune system’s response to the virus, contributing to the overgrowth of harmful bacteria like Enterococcus.
&nbs p;
There is also evidence that gut bacteria can influence immune responses in the lungs. The gut and lungs are connected by what is known as the “gut-lung axis,” which means that bacteria in the intestines can affect how the immune system responds to lung infections. This may explain why some COVID-19 patients experience both respiratory and gastrointestinal symptoms.
 
The Role of Antibiotics
Interestingly, the study also explored whether antibiotic use could explain the overgrowth of Enterococcus in COVID-19 patients. In hospitalized patients, antibiotics are commonly used to treat secondary infections, and these drugs can disrupt the gut microbiome by killing off beneficial bacteria, leaving room for harmful bacteria like Enterococcus to thrive.
 
However, the researchers did not find a significant difference in Enterococcus levels between COVID-19 patients who had received antibiotics and those who had not. This suggests that the bacterial overgrowth observed in these patients may not be solely due to antibiotic use, but could instead be a direct consequence of COVID-19 infection.
 
Microbiome Diversity and COVID-19 Severity
The study also looked at the overall diversity of gut bacteria in COVID-19 patients compared to the asymptomatic control group. It found that patients with COVID-19 had significantly lower diversity in their gut microbiomes. A less diverse microbiome is often associated with poorer health outcomes, as it can signal that harmful bacteria are dominating the gut environment.
 
The researchers used two metrics to measure diversity: Faith’s Phylogenetic Diversity and the Shannon Index. Both measures showed that COVID-19 patients had less complex microbiomes, indicating that the disease may disrupt the balance of bacteria in the gut. Lower microbiome diversity has been linked to other diseases, including inflammatory bowel disease and Parkinson’s disease, suggesting that this loss of diversity could be a marker of disease severity.
 
Enterococcus and Eggerthella in Other Populations
To better understand the significance of their findings, the researchers compared their data from Uganda with data from studies conducted in the United States. They found that Enterococcus blooms had also been reported in COVID-19 patients in the US, suggesting that this overgrowth may be a common feature of the disease, regardless of geographical location. However, the prevalence of Enterococcus in healthy individuals was much lower in the US population compared to the Ugandan population.
 
This difference may be due to variations in diet, lifestyle, or underlying health conditions between the two populations. Enterococcus is known to thrive in environments where antibiotic use is common, and it has been associated with diseases like inflammatory bowel disease and rheumatoid arthritis. Further research is needed to understand whether Enterococcus overgrowth is a direct cause of COVID-19 severity or a consequence of the disease.
 
Implications for Treatment
The findings from this study suggest that the gut microbiome may play an important role in how COVID-19 progresses. Understanding how the virus interacts with gut bacteria like Enterococcus could help researchers develop new treatments for the disease. For example, probiotics - live bacteria that promote gut health - could potentially be used to restore balance to the microbiome and reduce the risk of severe illness.
 
The researchers also suggest that future studies should explore whether Enterococcus blooms are a cause or consequence of COVID-19. Experimental models or prospective cohort studies will be needed to answer this question definitively.
 
Conclusion
This study highlights the critical role of the gut microbiome in COVID-19 and its potential impact on disease severity. The overgrowth of harmful bacteria like Enterococcus in COVID-19 patients could be a sign of gut dysbiosis, which may contribute to worsened outcomes. Although the study did not find a direct link between antibiotic use and Enterococcus blooms, it raises important questions about how the gut-lung axis and immune system interact during COVID-19 infection.
 
Further research is needed to understand the full extent of the relationship between the gut microbiome and COVID-19. By studying these interactions, researchers may be able to develop new strategies for preventing severe illness and improving outcomes for COVID-19 patients.
 
The study findings were published on a preprint server and are currently being peer reviewed.
https://www.medrxiv.org/content/10.1101/2024.09.28.24314457v1
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/compared-to-earlier-sars-cov-2-variants,-omicron-causes-a-greater-degree-of-dysbiosis-of-the-intestinal-microbiota
 
https://www.thailandmedical.news/news/covid-19-news-hong-kong-study-shows-that-lower-gut-abundance-of-eubacterium-rectale-is-linked-to-covid-19-mortality